Advancing the design and reliability of healthcare research through statistics.
At the Centre for Statistics in Medicine (CSM), I provide statistical support to the design, conduct and analysis of clinical trials. I am the trial statistician for the IntReALL2010 project, which encompasses two trials across 22 countries on first relapsed acute lymphoblastic leukaemia in children. The project aims to develop an optimised, internationally recognised standard therapy and investigate new therapeutic agents for these children. I am also the trial statistician for the phase I trial NuTide:301, a dose escalation and expansion study to assess the safety and clinical activity of a new anti-cancer agent in patients with solid tumours.
I collaborate on a range of other health research projects, where I contribute statistical expertise. For example, I advise on statistical methods, prepare statistical analysis plans, and undertake analyses. I am working on vaccine studies in flu and malaria prevention, and am involved in health intervention trials assessing the effectiveness of nutritional supplementation and palliative care. I also collaborate on systematic reviews, for example on the safety of cholinesterase inhibitors in Alzheimer’s disease.
I have a BSc in Biology from University College London and an MSc in Medical Statistics from the London School of Hygiene and Tropical Medicine. My MSc research project is titled Efficiency of a prospective pharmacogenetic study. I joined CSM in October 2015.
Brims F. et al, (2019), Thorax, 74, 354 - 361
The Relationship of Quality of Life, Physical Symptoms and Survival in Mesothelioma - Exploratory Analyses from the Respect-Meso Study
Brims F. et al, (2019), American journal of respiratory and critical care medicine, 199
A randomised controlled trial to assess the impact of regular early specialist symptom control treatment on quality of life in malignant mesothelioma - 'RESPECT-Meso'
Brims F. et al, (2018), British journal of cancer, 119, 10 - 11
A phase I first-in-human, dose-escalation and expansion study to evaluate the safety and tolerability of NUC-3373 in patients with locally advanced, unresectable or metastatic solid malignancies
Blagden S. et al, (2018), Annals of oncology, 29
Andrew MJ. et al, (2018), Dev med child neurol, 60, 906 - 913